The ALS Therapy Development Institute (ALS TDI) and startup company Denali Therapeutics have launched a new partnership to explore potential new ALS clinical trial endpoints, with the aim to improve tracking of disease progression and effects of therapeutic interventions in ALS clinical trials. A related study to identify novel ALS outcome measures for clinical trials is being conducted by Biogen (see Feb 2016 news).
The partners will analyze data collected through ALS TDI’s Precision Medicine Program (PMP). In addition to health surveys and ALS Functional Rating Scale-Revised (ALSFRS-R) data, the PMP data includes disease progression data collected in automated fashion through accelerometers worn by PMP participants. These wearable tracking devices collect data on motor function that could potentially provide improved endpoints for tracking ALS disease progression. Ultimately, improved endpoints have the potential to reduce the cost and time needed to determine drug efficacy in ALS clinical trials.
Click here to read more.